drugset

drugset / Trial / NCT07039669

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07039669 ↗

Phase 3 Recruiting 594 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Timeline

Start: 2025-07-16
Primary completion: 2028-09
Completion: 2028-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	611	Unknown	—	Subcutaneous

Indications